Last reviewed · How we verify
NCT06180213
Study of Cerebral Glucose Metabolism in Neurodegenerative Diseases and Head Trauma
trial testing FDG PET in Neurodegenerative Diseases in 1,570 participants. Completed in 31 December 2019.
31 December 2019
Quick facts
| Lead sponsor | IRCCS San Raffaele |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 1,570 |
| Start date | 1 October 2015 |
| Primary completion | 31 December 2019 |
| Estimated completion | 31 December 2019 |
Drugs / interventions tested
- FDG PET
Conditions studied
- Neurodegenerative Diseases — all drugs for Neurodegenerative Diseases →
Sponsor
IRCCS San Raffaele — full company profile →
Who can join
18 and older, any sex, with Neurodegenerative Diseases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The reason why each specific degenerative disease is characterized by a different FDG PET pattern is still unclear today. There are four main hypotheses proposed to explain this selective vulnerability: 1) Nodal stress, theory according to which the main nodes of specific brain networks undergo wear and tear, 2) trans-neuronal diffusion, theory according to which some toxic agents/proteins or altered propagate along network connections through "Prion-like" mechanisms, 3) trophic failure, in which the interruption of inter-modal connectivity causes the loss of collateral trophic factors, and finally 4) shared vulnerability in which regions also distant from each other are part of a common network which gives a susceptibility uniformly distributed throughout the network. FDG PET provides in-vivo information on the distribution of brain synaptic dysfunction prior to complete neural death, and represents the main in vivo biomarker of neural dysfunction associated with different clinical conditions characterized by neurodegeneration phenomena. For this reason, FDG PET is considered a fundamental approach to shed light on the causes of selective brain vulnerability in various pathological conditions.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06180213
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of FDG PET
Trials testing the same drug.
- NCT06335914 — Dual PSMA and FDG PET Imaging for Patients With Advanced Prostate Cancer · NA · recruiting
- NCT06079294 — Impact of Confirmed Autoimmune Encephalitis on Brain Glucose Metabolism · NA · recruiting
- NCT04566185 — Evaluation of the Predictive Value of 18F-fluorodeoxyglucose Positron Emission Tomography and Brain Perfusion Computed T · NA · completed
- NCT04255628 — The Brain Metabolic Change in Chronic Cancer Pain Patient: FDG PET Image Study · unknown
- NCT04174456 — Combination of Olmesartan Effect on Myocardial Viability of Patients With Dilated Cardiomyopathy · NA · unknown
Other recruiting trials for Neurodegenerative Diseases
Currently open trials in the same condition.
- NCT07324330 — Slowing Cognitive Decline in Alpha-synucleinopathies by Enhancing Physical Activity · NA · recruiting
- NCT07268079 — Validation of the VIRADIA App for Neurological and Cognitive Diagnostics in Virtual Reality · recruiting
- NCT07514520 — Decision-making, Ethical Consent, and Interactive Dialogue in Ongoing Neurocognitive Decline - DECISION · active not recruiting
- NCT06755840 — Sleep Disordered Breathing and Multimorbidity: The Xiangya SDB Cohort Study · recruiting
- NCT06596746 — Neurodegenerative Diseases Progression Markers (MARKERS-NDD) · recruiting
Other IRCCS San Raffaele trials
Trials by the same sponsor.
- NCT07454759 — Acute Sarcopenia in Hospitalized Older Adults · not yet recruiting
- NCT07456462 — Making Antibody Treatments More Effective in Early Alzheimer's Disease Using 3Tesla Magnetica Resonance · NA · not yet recruiting
- NCT07066878 — This Protocol Focuses on the Factors That Influence Survival, the Development of Complications and the Quality of Life B · not yet recruiting
- NCT07526298 — Anticipating Irreversible Disability in Neuromyelitis Optica Spectrum Disorder: a Study to Assess Disease Activity in Ap · not yet recruiting
- NCT07426471 — Delafloxacin Plasma and Tissue Concentration in Patients With Skin, Soft Tissue, and Bone and Joint Infections. · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06180213 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by IRCCS San Raffaele
- Last refreshed: 22 December 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06180213.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing